Esperion Therapeutics (ESPR) M&A announcement summary

Deal rationale and strategic fit

• Acquisition expands the cardiovascular franchise with ENBUMYST, the first FDA-approved nasal spray loop diuretic for edema in heart failure, hepatic, and renal disease, complementing the existing portfolio and leveraging established commercial infrastructure.

• ENBUMYST addresses significant unmet needs in outpatient management of fluid overload, offering a unique, patient-friendly delivery method that bypasses GI absorption issues common with oral diuretics.

• The deal aligns with long-term strategy to diversify the product portfolio, achieve at least five marketed products by 2040, and deliver differentiated cardiovascular innovations.

• ENBUMYST provides entry into a $4+ billion addressable outpatient heart failure market, with potential for global expansion and outreach.

• Acquisition builds on expertise in cardiovascular, metabolic, hepatic, and renal diseases, supporting Vision 2040 and sustained double-digit revenue growth.

Financial terms and conditions

• Upfront cash payment of $75 million, up to $180 million in milestone payments tied to regulatory and commercial achievements, and low double-digit royalties on worldwide ENBUMYST sales and follow-on products.

• Financing is structured through a combination of debt, existing credit facilities, and royalty monetization, avoiding dilution and maintaining a strong balance sheet.

Synergies and expected cost savings

• Leverages established cardiovascular commercial infrastructure, payer contracts, and sales force for efficient launch, rapid integration, and market penetration.

• ENBUMYST complements current oral therapies, targets the same physician base, and maximizes cross-selling opportunities.

• Potential to reduce CHF hospitalizations and associated costs by enabling at-home treatment and reducing readmissions, supporting value-based care models.

• Differentiated product form factor may improve patient adherence and outcomes.

• Expected to accelerate double-digit revenue growth and contribute to sustainable profitability by 2026.